GNH USA

Europe — EMA

Mresvia

GNH USA supplies Mresvia (Single-Stranded 5' Capped mRNA), a vaccine for prevention of respiratory syncytial virus infection.

Single-Stranded 5' Capped Mrna Encoding The Respiratory Syncytial Virus Glycoprotein F Stabilized In

Request sourcing

1
Pack/s

What is Single-Stranded 5' Capped Mrna Encoding The Respiratory Syncytial Virus Glycoprotein F Stabilized In?

Single-Stranded 5' Capped mRNA encoding RSV F glycoprotein, the active ingredient in Mresvia, is a vaccine presented as a vaccine formulation for intramuscular use. It prevents respiratory syncytial virus infection in at‑risk populations, including infants, older adults and immunocompromised individuals.

GNH USA supplies Mresvia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

What is Single-Stranded 5' Capped Mrna Encoding The Respiratory Syncytial Virus Glycoprotein F Stabilized In used for?

Mresvia is a vaccine that targets the respiratory syncytial virus (RSV) pathway to provide prophylactic protection. - Respiratory syncytial virus infection: reduces the incidence of RSV disease in vaccinated individuals. - High‑risk populations (infants, elderly, immunocompromised): lowers the risk of severe lower respiratory tract illness caused by RSV. - Seasonal RSV outbreaks: contributes to community health by decreasing overall RSV transmission.

What are the side effects of Single-Stranded 5' Capped Mrna Encoding The Respiratory Syncytial Virus Glycoprotein F Stabilized In?

Mresvia may cause a range of adverse reactions following intramuscular administration.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or swelling: localized erythema or edema. - Fever: transient elevation of body temperature. - Headache: mild to moderate headache. - Fatigue: general feeling of tiredness. - Myalgia: muscle aches.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Guillain‑Barré syndrome: rare autoimmune neuropathy. - Myocarditis: inflammation of the heart muscle. - Severe allergic reaction: including angioedema. - Seizures: uncommon neurologic event. - Thrombotic events: rare clotting disorders.

What precautions apply to Single-Stranded 5' Capped Mrna Encoding The Respiratory Syncytial Virus Glycoprotein F Stabilized In?

Before administering Mresvia, consider the following safety measures. - Pregnancy: safety has not been established; use only if benefit outweighs risk. - Breastfeeding: caution advised; limited data on excretion in milk. - Immunocompromised patients: evaluate potential reduced efficacy. - Known hypersensitivity: avoid in individuals with allergy to any vaccine component. - Concomitant vaccines: consult healthcare professional regarding timing. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

What does Single-Stranded 5' Capped Mrna Encoding The Respiratory Syncytial Virus Glycoprotein F Stabilized In interact with?

Mresvia may interact with other medications or vaccines, requiring clinical awareness.

Major Interactions (Avoid): - Live attenuated vaccines: avoid co‑administration within 4 weeks to prevent interference. - High‑dose immunosuppressants: may markedly diminish vaccine response.

Moderate Interactions (Monitor Closely): - Antipyretics (e.g., acetaminophen): may mask post‑vaccination fever. - Other injectable vaccines: can be given concomitantly but monitor for increased reactogenicity. - Corticosteroids: may modestly reduce immunogenicity; assess timing.

Frequently asked questions

What is Mresvia used for?+
Mresvia is a vaccine indicated for the prevention of respiratory syncytial virus (RSV) infection. It is designed to protect individuals at risk of severe RSV disease, such as infants, older adults, and immunocompromised patients, by stimulating an immune response against the RSV F glycoprotein.
How does the active ingredient in Mresvia work?+
The active ingredient is a single‑stranded 5' capped mRNA that encodes the RSV F glycoprotein. After intramuscular injection, host cells translate the mRNA into the F protein, which is then recognized by the immune system, prompting the production of neutralizing antibodies and cellular immunity that protect against future RSV exposure.
What is the usual dose of Mresvia?+
The dosage and administration schedule for Mresvia are determined by the prescribing healthcare professional based on the patient’s age, health status, and local immunization guidelines. The prescriber will set the appropriate dose and timing for each individual.
Is Mresvia safe to use during pregnancy or breastfeeding?+
Safety data for Mresvia in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers should discuss individual risks and benefits with patients.
How do I order Mresvia from GNH USA?+
To place an order, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA supplies hospitals, pharmacies, and procurement teams worldwide. After verification of trade or institutional credentials, the sales team will provide pricing, availability, shipping details (including cold‑chain logistics if needed), and required import documentation.
How does Mresvia compare with other RSV vaccines?+
Mresiva uses an mRNA platform to express the RSV F glycoprotein, whereas many existing RSV vaccines are based on recombinant protein or live‑attenuated virus technologies. The mRNA approach can offer rapid manufacturing and potentially broader immune responses, but comparative efficacy and safety are evaluated in clinical studies specific to each product.
What are the storage and handling requirements for Mresvia?+
Mresvia must be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and avoid freezing or shaking. Maintaining the cold chain during transport and storage is essential to preserve vaccine potency.
How is Mresvia administered?+
Mresvia is given by intramuscular injection, typically into the deltoid muscle. The injection should be performed by a qualified healthcare professional following aseptic technique and according to the prescribed dosing schedule.
What are the most serious risks associated with Mresvia?+
Serious adverse events, although rare, can include anaphylaxis, Guillain‑Barré syndrome, myocarditis, severe allergic reactions, seizures, and thrombotic events. Patients should be observed after vaccination and seek immediate medical care if any severe symptoms develop.
Who should not receive Mresvia?+
Mresvia should not be administered to individuals with a known severe allergy to any component of the vaccine. It is also contraindicated in persons who have experienced a previous severe reaction to an RSV vaccine. Clinical judgment is required for patients with compromised immune systems or other special conditions.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Single-Stranded 5' Capped Mrna Encoding The Respiratory Syncytial Virus Glycoprotein F Stabilized In
Route
Intramuscular Use
Manufacturer
Moderna Biotech Spain S. L.
Origin
EU